In this single-center analysis, we evaluated the trends in 5185 hematopoietic cell transplantations performed between 1990 and 2022. The study group comprised 3237 allogeneic (alloHCT) and 1948 autologous (autoHCT) hematopoietic cell transplantations. In the multivariate analysis, there was an improvement in event-free-survival (EFS) after autoHCT (HR 0.6, 95% CI 0.4–0.7,p< 0.0001) due to reduced cumulative incidence of relapse in the last five years (56% in 2010–2014 vs. 38% in 2015–2022). An improvement in EFS after alloHCT over time was observed (HR 0.33, 95% CI 0.23–0.48,p< 0.0001), which was due to reduced non-relapse mortality. No difference in cumulative relapse incidence was observed over the last decade for allografted patients. Survival after autoHCT improved in Hodgkin’s disease (HR 0.1, 95% CI 0.1–0.3), multiple myeloma (HR 0.4, 95% CI 0.2–0.7) and solid tumors (HR 0.2, 95% CI 0.2–0.4), while after alloHCT, improvement was observed in acute myeloid leukemia (HR 0.3, 95% CI 0.1–0.5), acute lymphoblastic leukemia (HR 0.2, 95% CI 0.1–0.5), Hodgkin’s disease (HR 0.1, 95% CI 0.0–0.4), non-Hodgkin’s lymphomas and chronic lymphocytic leukemia (HR 0.2, 95% CI 0.0–0.6), inborn diseases (HR 0.2, 95% CI 0.2–0.4) and acquired aplastic anemia with matched related donors and matched unrelated donors (HR 0.3, 95% CI 0.2–0.8).
在这项单中心分析中，我们评估了1990年至2022年间实施的5185例造血细胞移植的趋势。研究组包括3237例异基因造血细胞移植（alloHCT）和1948例自体造血细胞移植（autoHCT）。多变量分析显示，autoHCT后的无事件生存率（EFS）有所改善（HR 0.6, 95% CI 0.4–0.7, p < 0.0001），这归因于近五年累积复发率的降低（2010–2014年为56% vs. 2015–2022年为38%）。同时观察到alloHCT后的EFS随时间推移而改善（HR 0.33, 95% CI 0.23–0.48, p < 0.0001），这主要得益于非复发死亡率的降低。在过去十年中，异基因移植患者的累积复发率未见显著差异。autoHCT后生存率在霍奇金病（HR 0.1, 95% CI 0.1–0.3）、多发性骨髓瘤（HR 0.4, 95% CI 0.2–0.7）和实体瘤（HR 0.2, 95% CI 0.2–0.4）中得到改善；而alloHCT后则在急性髓系白血病（HR 0.3, 95% CI 0.1–0.5）、急性淋巴细胞白血病（HR 0.2, 95% CI 0.1–0.5）、霍奇金病（HR 0.1, 95% CI 0.0–0.4）、非霍奇金淋巴瘤及慢性淋巴细胞白血病（HR 0.2, 95% CI 0.0–0.6）、先天性疾病（HR 0.2, 95% CI 0.2–0.4）以及获得性再生障碍性贫血（使用匹配相关供者和匹配无关供者时HR 0.3, 95% CI 0.2–0.8）中观察到改善。
肿瘤(癌症)患者之家